IXICO (FRA:PYPB) Net Income From Continuing Operations : €-2.18 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is IXICO Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. IXICO's net income from continuing operations for the six months ended in Mar. 2024 was €-1.65 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.18 Mil.

IXICO Net Income From Continuing Operations Historical Data

The historical data trend for IXICO's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Net Income From Continuing Operations Chart

IXICO Annual Data

Trend

Sep13

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Net Income From Continuing Operations

Get a 7-Day Free Trial

0.49

1.05

1.77

1.18

-1.37

IXICO Semi-Annual Data
	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															0.20	0.99	-0.82	-0.53	-1.65

IXICO Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.18 Mil.

IXICO (FRA:PYPB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (FRA:PYPB) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

PHYOF:USA IXI:UK

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (FRA:PYPB) Headlines

No Headlines